Mitoconix Bio

06/27/2017

Mitoconix Bio

Mitoxonix Bio is a Israel based private drug discovery company targeting mitochondrial dynamism as its strategy to develop new therapies for neurodegenerative diseases. Excessive mitochondrial fragmentation resulting in small and dysfunctional mitochondria is a central pathological process in human diseases and specifically neurodegeneration . Mitoconix Bio’s lead product MTC-1203, is a first-in-class selective inhibitor of excessive mitochondrial division for treating Huntington’s disease and other neurodegenerative disorders. MTC-1203 has demonstrated efficacy in mouse models of Huntington’s and Parkinson's diseases.